Ciphergen Announces Issuance of Patent for Protein Pattern Recognition Combined with Mass Spectrometry
January 07 2004 - 4:15PM
PR Newswire (US)
Ciphergen Announces Issuance of Patent for Protein Pattern
Recognition Combined with Mass Spectrometry FREMONT, Calif., Jan. 7
/PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced
today that the United States Patent and Trademark Office has issued
Ciphergen U.S. Patent 6,675,104, directed to finding protein
patterns in mass spectrometry data. The patent covers software and
methods that use a pattern recognition algorithm, called
"classification and regression tree analysis," or CART, to identify
diagnostic patterns of proteins derived from mass spectrometry
data. This method is used in Ciphergen's Biomarker Patterns(TM)
Software and SELDI ProteinChip(R) Biomarker System for biomarker
discovery, validation and assay development. "We believe this
classification approach will enable development of a new generation
of more predictive, higher value, clinical diagnostic and
prognostic tests," said William E. Rich, President and CEO of
Ciphergen. "Together with SELDI-MS, this method forms a powerful
'diagnostic pattern discovery technology' which enables rapid
discovery of patterns of discreet, identifiable protein biomarkers
in human fluids and tissues that distinguish disease states from
healthy ones. These protein patterns can then be used to rapidly
develop multi-marker, diagnostic assays. Ciphergen has long
believed that protein multi-marker tests are the future of clinical
diagnostics and will also enable pharmacoproteomics, which includes
protein-based predictive toxicology and clinical trial patient
stratification in pharmaceutical drug development leading to new
companion diagnostics." About Ciphergen Ciphergen develops,
manufactures and markets a family of ProteinChip(R) Systems and
services for clinical, research and process proteomics
applications, as well as a broad range of bioseparations media for
protein purification through its BioSepra process chromatography
division. ProteinChip Systems and Biomarker Discovery Center(R)
collaborative services enable protein discovery, profiling,
characterization and assay development to provide researchers with
predictive analysis capabilities and a better understanding of
biological functions at the protein level. ProteinChip Systems are
enabling tools in the emerging field of protein-based biology
research, known as proteomics. Proteomics provides a direct
approach to understanding the role of proteins in the biology of
disease, monitoring disease progression and evaluating the
therapeutic effects and side effects of drugs. Ciphergen believes
proteomics will be a major focus of biological research by
enhancing the understanding of gene function and the molecular
basis of disease. Additional information about Ciphergen can be
found at http://www.ciphergen.com/. Safe Harbor Statement Note
Regarding Forward-Looking Statements: For purposes of the Private
Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
forward-looking statements include statements regarding our ability
to develop, and the characteristics of, new diagnostic and
prognostic tests, the enabling power of SELDI ProteinChip
technology to discover and assay useful biomarkers, the expected
benefits of using the new classification approach with SELDI-MS,
the expectation that protein multi-marker tests will have a
significant future role in diagnostics, prognostics, predictive
toxicology and drug development, and future growth in the field of
proteomics. Actual results may differ materially from those
projected in such forward-looking statements due to various
factors, including ProteinChip technology's ability to successfully
discover, validate and assay biomarkers and patterns of biomarkers
that are highly predictive and therefore meet with customer
acceptance, the continued emergence of proteomics as a major focus
of biological research and drug discovery, and our ability to
protect and promote our proprietary technologies. Investors should
consult Ciphergen's filings with the Securities and Exchange
Commission, including its Form 10-Q dated November 14, 2003, for
further information regarding these and other risks of the
Company's business. NOTE: Ciphergen, ProteinChip, Biomarker
Discovery Center and BioSepra are registered trademarks of
Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: Sue Carruthers of Ciphergen Biosystems, Inc., +1-510-505
2233 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024